breast cancer - HER2-positive | ||
es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | |
trastuzumab based treatment | ||
trastuzumab plus endocrine therapy | SYSUCC-002 | |
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel |